Benzinga | May 4, 2021 10:18AM EDT

Barclays Maintains Overweight on Ligand Pharmaceuticals, Lowers Price Target to $190

Barclays analyst Balaji Prasad maintains Ligand Pharmaceuticals (NASDAQ:LGND) with a Overweight and lowers the price target from $198 to $190.